ProQR Therapeutics NV (NASDAQ:PRQR)’s share price traded down NaN on Tuesday . The company traded as low as $5.20 and last traded at $0.00. 1,161,880 shares were traded during trading, an increase of Infinity from the average session volume of 0 shares.

A number of equities analysts recently weighed in on the stock. Leerink Swann restated an “outperform” rating and set a $12.00 price target (up from $10.00) on shares of ProQR Therapeutics NV in a research report on Tuesday. HC Wainwright reaffirmed a “buy” rating and set a $40.00 target price on shares of ProQR Therapeutics NV in a research note on Tuesday, June 20th. JMP Securities lifted their target price on shares of ProQR Therapeutics NV from $14.00 to $20.00 and gave the stock an “outperform” rating in a research note on Tuesday. ValuEngine downgraded shares of ProQR Therapeutics NV from a “hold” rating to a “sell” rating in a research note on Tuesday. Finally, Chardan Capital reaffirmed a “neutral” rating on shares of ProQR Therapeutics NV in a research note on Sunday, September 17th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the company. ProQR Therapeutics NV presently has a consensus rating of “Hold” and an average target price of $14.92.

The company’s market cap is $122.94 million. The stock’s 50 day moving average price is $5.12 and its 200-day moving average price is $5.00.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Redmile Group LLC raised its holdings in ProQR Therapeutics NV by 2.8% in the second quarter. Redmile Group LLC now owns 1,596,275 shares of the biopharmaceutical company’s stock valued at $8,301,000 after buying an additional 43,050 shares during the period. Artal Group S.A. raised its holdings in ProQR Therapeutics NV by 25.0% in the second quarter. Artal Group S.A. now owns 500,000 shares of the biopharmaceutical company’s stock valued at $2,600,000 after buying an additional 100,000 shares during the period. Finally, Janus Henderson Group PLC purchased a new position in ProQR Therapeutics NV in the second quarter valued at approximately $2,028,000. Hedge funds and other institutional investors own 35.93% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “ProQR Therapeutics NV (PRQR) Trading Down NaN” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://www.thecerbatgem.com/2017/09/28/proqr-therapeutics-nv-prqr-trading-down-nan.html.

ProQR Therapeutics NV Company Profile

ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Utilizing its RNA repair technologies, the Company is developing a pipeline in severe genetic disorders, such as cystic fibrosis (CF) and Leber’s congenital amaurosis (LCA).

Receive News & Stock Ratings for ProQR Therapeutics NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics NV and related stocks with our FREE daily email newsletter.